Eli Lilly and Company (LLY)
Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs
Eli Lilly has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company's investigational weight-loss drug on the black market.
Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run
Eli Lilly (NYSE:LLY | LLY Price Prediction) delivered a monster quarter with revenue growth, a fourth consecutive EPS beat, and a fresh guidance raise.
Eli Lilly and Company Q2 Earnings Call Highlights
Eli Lilly and Company NYSE: LLY reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance.
Eli Lilly: Fine Q2 2026 Results, But Alertness Required
Eli Lilly's latest results made investors happy, as the stock jumped 5% on their release, as both revenues and earnings grew by strong double-digit percentages. While the company's blockbuster diabetes treatment Mounjaro led revenue growth, Zepbound gives some reasons for concern, along with other treatments. Strong margins and upgraded revenue guidance still significantly add to the stock, even as the EPS outlook was trimmed a bit.
LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
Lilly lifts its 2026 outlook as Foundayo adoption accelerates, Medicare expands obesity access and retatrutide advances toward a 2027 filing.
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growing divide in Wall Street's confidence in the two obesity drug giants.
Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis
Eli Lilly remains a buy after Q2, with robust revenue growth and strong performance from Mounjaro and Zepbound. LLY raised 2026 revenue guidance to $85–87 billion, driven by volume gains despite price declines, and reinforced margin expansion. Retatrutide is a key medium-term catalyst, with a BLA submission planned for Q1 2027 and potential in new therapeutic areas.
Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript
Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript
Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026
CNBC Business News Update with Peter Schacknow - Markets & Business News With Expert Analysis From Top Business Names. Visit CNBC.com For More.
Eli Lilly's Weight-Loss Drug Demand Is Nearly Limitless. Here's What Comes Next for the $1 Trillion Drugmaker
Eli Lilly (NYSE:LLY | LLY Price Prediction) opened Wednesday's session with a blowout second-quarter earnings report, sending shares sharply higher and cementing the drugmaker's status as the only pharmaceutical company trading above a $1 trillion market cap.
Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly shares rise on revenue beat, raised outlook
Eli Lilly and Co (NYSE:LLY) shares rose nearly 7% in early trading Wednesday after the drugmaker reported second quarter results that topped Wall Street revenue expectations and raised its full-year 2026 revenue outlook, with strong demand for its Mounjaro and Zepbound weight-loss and diabetes treatments driving a sharp increase in sales. Lilly reported second quarter revenue of $22.97 billion, up 48% from $15.56 billion a year earlier and above Wall Street estimates of roughly $20.6 billion.
